ELAN Q3 2025 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.1B+10.4% YoY

Gross Profit

$607M53.4% margin

Operating Income

$27M2.4% margin

Net Income

-$34M-3.0% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

-8.4%

Cash Flow

Operating Cash Flow

$219M

Free Cash Flow

$127M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$13.6B

Total Liabilities

$6.8B

Stockholders' Equity

$6.7B

Cash & Equivalents

$505M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$1.0B	+10.4%
Gross Profit	$607M	$405M	+49.9%
Operating Income	$27M	-$5M	+640.0%
Net Income	-$34M	$364M	-109.3%

Revenue Segments

Farm Animal

$593M34%

Pet Health

$533M31%

Cattle

$289M17%

Poultry

$217M13%

Swine

$87M5%

Contract Manufacturing

$11M1%

Geographic Segments

Non-US

$590M52%

UNITED STATES

$547M48%